William Blair Reiterates Outperform for Viridian, Target Undisclosed
1h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
viridian-therapeuticsbiotech-stock
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Analysts at William Blair reaffirmed their Outperform rating on shares of Viridian Therapeutics, Inc. on 29 June 2026, according to a note to clients. The firm did not publish a new price target alongside the reiteration. The biotechnology company's stock closed at $24.19 on the prior trading day, placing its market capitalization at approximately $1.25 billion. The analyst action arrives ahead of a critical clinical catalyst for Viridian's lead candidate, VRDN-003, expected before the end of the year.
Analyst reiterations ahead of binary clinical data readouts are a common but high-stakes pattern in biotechnology. In October 2023, Madrigal Pharmaceuticals stock surged over 260% in a single day after the FDA accepted its NDA for resmetirom, following months of supportive analyst coverage. The current macro backdrop for high-growth biotech remains challenging, with the iShares Biotechnology ETF (IBB) down 4% year-to-date as of late June 2026, underperforming the broader S&P 500.
What triggered this specific reaffirmation now is the impending Phase 3 THRIVE trial data readout for VRDN-003 in thyroid eye disease. Top-line results are anticipated in the fourth quarter of 2026. The timing suggests William Blair is signaling confidence in the trial's design and execution ahead of the data release. Thyroid eye disease represents a market exceeding $3 billion annually, creating significant commercial potential for a successful entrant.
Viridian's stock performance reflects the volatile nature of clinical-stage biotech investing. The share price has a 52-week range of $16.05 to $42.80, indicating a high degree of implied volatility around clinical milestones. The stock's current price of $24.19 represents a decline of over 40% from its 52-week high, set in late 2025.
A comparison of key metrics against a peer, Horizon Therapeutics (now part of Amgen), which successfully commercialized the TED drug Tepezza, is illustrative. Horizon's market cap grew from approximately $2 billion in 2017 to over $20 billion prior to its acquisition, driven by Tepezza's peak annual sales forecast of nearly $4 billion. Viridian's VRDN-003 aims to challenge Tepezza with a potential dosing advantage. The average analyst price target for VRDN from other firms, according to consensus data, is $38.50, implying a potential upside of nearly 60% from current levels.
The primary second-order effect of a positive VRDN-003 readout would be downward pressure on the market share of Amgen's Tepezza. A successful trial could shift an estimated 15-25% of the future TED market to Viridian over a three-year launch period, translating to hundreds of millions in potential lost revenue for Amgen's product. Conversely, contract development and manufacturing organizations like Lonza Group, which likely supports Viridian's supply chain, would see increased demand.
A key limitation and counter-argument is the high clinical failure rate in late-stage trials, even for well-regarded candidates. The Phase 3 trial must not only hit its primary efficacy endpoint but also demonstrate a superior safety and convenience profile to gain meaningful market share in a market with an established, effective therapy. Positioning data indicates institutional ownership of Viridian has remained steady near 85%, but short interest sits at approximately 12% of float, reflecting a meaningful cohort betting on trial failure.
The definitive catalyst is the THRIVE Phase 3 trial top-line data release, expected in Q4 2026. Investors should monitor the specific week of October or November for an announcement. Following the data, Viridian's subsequent action will be to file a Biologics License Application with the FDA, likely in the first half of 2027.
Key technical levels for the stock include immediate support at the $22.50 level, which has held twice in 2026, and major resistance at the 200-day moving average, currently near $28.75. A break above this average on heavy volume would signal a shift in intermediate-term momentum. The primary conditional factor is the trial's outcome: positive data likely initiates a re-rating toward the peer-group valuation of commercial-stage rare disease companies, while negative data would pressure the stock toward its cash value per share, estimated near $8.00.
An Outperform rating from an investment bank like William Blair is a recommendation that the stock is expected to deliver a total return exceeding that of the relevant benchmark or sector average over the next 12-18 months. For a pre-revenue biotech firm, this rating is almost entirely contingent on clinical success and is a direct expression of analyst confidence in an upcoming binary event. It does not guarantee performance and is distinct from a price target, which provides a specific valuation estimate.
VRDN-003 is a subcutaneous injectable monoclonal antibody targeting the IGF-1R pathway, similar to the approved drug Tepezza. Its key purported differentiation is a less frequent dosing regimen. Tepezza is administered via intravenous infusion every three weeks. If VRDN-003 demonstrates comparable efficacy with a more convenient subcutaneous injection given less frequently, it could capture market share based on patient and provider preference, potentially in a home-setting, which reduces clinic burden.
Historical success rates vary by therapeutic area. For oncology, Phase 3 to approval success is around 40-45%, while for rare diseases and metabolic disorders, the probability can be higher, often cited between 50-60%. This elevated rate is due to smaller trial sizes, high unmet need, and sometimes more predictable biology. However, the transition from Phase 2 to Phase 3 remains a major risk, with many candidates failing due to inability to replicate earlier results in a larger, more diverse patient population.
William Blair's reiteration spotlights Viridian's stock as a pure-play, high-risk binary bet on the Q4 2026 THRIVE trial data for VRDN-003.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.